United Therapeutics Co. (NASDAQ:UTHR) Receives $382.08 Consensus Target Price from Analysts

Shares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $382.08.

Several equities analysts recently issued reports on the stock. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, January 16th. HC Wainwright increased their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st.

United Therapeutics Stock Down 1.7 %

UTHR traded down $6.26 on Tuesday, reaching $361.10. 407,154 shares of the company traded hands, compared to its average volume of 346,908. United Therapeutics has a one year low of $214.75 and a one year high of $417.82. The company has a market cap of $16.12 billion, a P/E ratio of 15.86, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57. The firm has a fifty day simple moving average of $362.70 and a two-hundred day simple moving average of $359.94.

Insiders Place Their Bets

In other news, Director Nilda Mesa sold 255 shares of the business's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now directly owns 5,528 shares of the company's stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $960,576.75. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 124,164 shares of company stock worth $45,398,793. 11.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wealthfront Advisers LLC raised its position in shares of United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the period. Vanguard Group Inc. raised its position in United Therapeutics by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock valued at $1,567,253,000 after buying an additional 32,213 shares during the period. FMR LLC raised its position in United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after buying an additional 393,777 shares during the period. Geode Capital Management LLC raised its position in United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock valued at $401,184,000 after buying an additional 44,277 shares during the period. Finally, AQR Capital Management LLC raised its position in United Therapeutics by 0.8% during the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock valued at $344,176,000 after buying an additional 7,710 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.